Alto Neuroscience

The mid-stage misfire of Alto Neuroscience’s depression candidate ALTO-100 is not just bad – and predictable given that the asset had already failed in the disease – it also calls into question the co

FDA Advising CMS On RWE Studies Amid IRA Price Negotiations The US Food and Drug Administration is advising the Centers for Medicare and Medicaid Services on the types of real-world evidence research

FDA Advising CMS On RWE Studies Amid IRA Price Negotiations The US Food and Drug Administration is advising the Centers for Medicare and Medicaid Services on the types of real-world evidence research

Rapport Therapeutics Inc. charted a path for its initial public offering and executed the IPO according to the plan it laid out for investors, reaping a slight reward on its first day of trading on 7